Latest Insider Transactions at Kiniksa Pharmaceuticals, Ltd. (KNSA)
This section provides a real-time view of insider transactions for Kiniksa Pharmaceuticals, Ltd. (KNSA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Kiniksa Pharmaceuticals, Ltd. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Kiniksa Pharmaceuticals, Ltd.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 02
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
16,670
-49.5%
|
$316,730
$19.17 P/Share
|
|
Jan 02
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
16,670
+33.11%
|
$216,710
$13.88 P/Share
|
|
Dec 19
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
9,316
-35.39%
|
$177,004
$19.13 P/Share
|
|
Dec 19
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,316
+26.14%
|
$121,108
$13.88 P/Share
|
|
Dec 07
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
28,600
-11.4%
|
$486,200
$17.69 P/Share
|
|
Dec 07
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
28,600
+28.01%
|
$28,600
$1.86 P/Share
|
|
Nov 03
2023
|
Richard S Levy |
BUY
Exercise of conversion of derivative security
|
Direct |
2,777
+26.31%
|
-
|
|
Oct 04
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
52
-0.3%
|
$832
$16.01 P/Share
|
|
Oct 04
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
175
+1.02%
|
-
|
|
Sep 05
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
400
-0.88%
|
$6,800
$17.53 P/Share
|
|
Sep 05
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+0.88%
|
$400
$1.86 P/Share
|
|
Sep 02
2023
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
577
-0.47%
|
$9,809
$17.76 P/Share
|
|
Sep 02
2023
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,964
+1.56%
|
-
|
|
Sep 02
2023
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
547
-3.38%
|
$9,299
$17.76 P/Share
|
|
Sep 02
2023
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,861
+10.32%
|
-
|
|
Sep 02
2023
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,187
-4.0%
|
$37,179
$17.76 P/Share
|
|
Sep 02
2023
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,569
+10.72%
|
-
|
|
Sep 02
2023
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
543
-3.63%
|
$9,231
$17.76 P/Share
|
|
Sep 02
2023
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
994
+6.23%
|
-
|
|
Sep 02
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
228
-1.33%
|
$3,876
$17.76 P/Share
|
|
Sep 02
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
774
+4.33%
|
-
|
|
Sep 02
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
507
-1.12%
|
$8,619
$17.76 P/Share
|
|
Sep 02
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,725
+3.66%
|
-
|
|
Sep 01
2023
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
801
-0.65%
|
$13,617
$17.76 P/Share
|
|
Sep 01
2023
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,727
+2.17%
|
-
|
|
Sep 01
2023
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
791
-5.24%
|
$13,447
$17.76 P/Share
|
|
Sep 01
2023
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,695
+15.14%
|
-
|
|
Sep 01
2023
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,432
-8.43%
|
$75,344
$17.76 P/Share
|
|
Sep 01
2023
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,992
+15.97%
|
-
|
|
Sep 01
2023
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,353
-8.83%
|
$23,001
$17.76 P/Share
|
|
Sep 01
2023
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,477
+13.92%
|
-
|
|
Sep 01
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,155
-6.6%
|
$19,635
$17.76 P/Share
|
|
Sep 01
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,933
+18.36%
|
-
|
|
Sep 01
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
734
-1.65%
|
$12,478
$17.76 P/Share
|
|
Sep 01
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,498
+5.33%
|
-
|
|
Jul 25
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
29,000
-15.78%
|
$522,000
$18.98 P/Share
|
|
Jul 25
2023
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
29,000
+29.03%
|
$29,000
$1.86 P/Share
|
|
Jul 15
2023
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
292
+2.22%
|
$3,504
$12.35 P/Share
|
|
Jul 15
2023
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
581
+4.11%
|
$6,972
$12.35 P/Share
|
|
Jun 29
2023
|
Barry D Quart |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
-
|
|
Jun 29
2023
|
G Bradley Cole |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
-
|
|
Jun 29
2023
|
Kimberly J Popovits |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
-
|
|
Jun 29
2023
|
Richard S Levy |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
-
|
|
Jun 29
2023
|
Tracey L Mc Cain |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
-
|
|
Jun 29
2023
|
Thomas Malley |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
-
|
|
Jun 06
2023
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
17,492
+3.62%
|
-
|
|
Apr 26
2023
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
291
-2.29%
|
$3,201
$11.15 P/Share
|
|
Apr 26
2023
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
990
+7.23%
|
-
|
|
Apr 10
2023
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
791
-6.33%
|
$7,910
$10.71 P/Share
|
|
Apr 10
2023
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,695
+17.73%
|
-
|